Avalo Therapeutics, Inc. (AVTX) earnings date
Mar 26, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 27% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 40 days, typically, give or take 20 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | before open | 36 | 8-K |
| Q2 FY2026 | Thu, Aug 6, 2026 | before open | 37 | 8-K |
| Q1 FY2026 | Wed, May 13, 2026 | before open | 43 | 8-K |
| Q4 FY2025 | Mon, Mar 23, 2026 | before open | 82 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | before open | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 7, 2025 | before open | 38 | 8-K |
| Q1 FY2025 | Mon, May 12, 2025 | before open | 42 | 8-K |
| Q4 FY2024 | Thu, Mar 20, 2025 | before open | 79 | 8-K |
What they guided beta
| Q3 FY2026 | "Cash, cash equivalents and investments of $462.8 million as of September 30, 2026, expected to fund operations into 2029 WAYNE, Pa., Nov. 5, 2026 – Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company focused on developing therapies targeting the IL-1β pathway for immune-mediated inflammatory diseases, today reported financial results for the third quarter of 2026 and provided a business update." exhibit |
| Q3 FY2026 | "Avalo expects feedback from the U.S. Food and Drug Administration on its proposed development plan by year-end 2026 and plans to initiate the Phase 3 program in the first half of 2027." exhibit |
| Q3 FY2026 | "Avalo’s current cash, cash equivalents, and investments are expected to fund operations into 2029." exhibit |
| Q3 FY2026 | "These increases were partially offset by lower clinical expenses as LOTUS trial and related activities decreased following the topline data readout in May 2026." exhibit |
| Q2 FY2026 | "Cash, cash equivalents and investments of $472.2 million as of June 30, 2026, expected to provide runway into 2029 WAYNE, PA., August 6, 2026 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced business updates and financial results for the second quarter of 2026." exhibit |
| Q2 FY2026 | "The Company expects to submit an Investigational New Drug (IND) application in the first half of 2027." exhibit |
| Q2 FY2026 | "Avalo’s current cash, cash equivalents, and investments are expected to fund operations into 2029." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/AVTX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/AVTX
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/AVTX/"><img src="https://veritasdata.dev/embed/AVTX.svg" alt="AVTX earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/AVTX/)
Script
<script async src="https://veritasdata.dev/embed/AVTX.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/AVTX"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.